KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Equity Ratio data on record, last reported at 0.76 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 3701.35% year-over-year to 0.76; the TTM value through Dec 2025 reached 0.76, up 3701.35%, while the annual FY2025 figure was 0.76, 3701.35% up from the prior year.
  • Equity Ratio reached 0.76 in Q4 2025 per RIGL's latest filing, up from 0.48 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.76 in Q4 2025 and bottomed at 0.28 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.06, with a median of 0.0 recorded in 2022.
  • Peak YoY movement for Equity Ratio: plummeted 735.86% in 2023, then soared 3701.35% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.18 in 2021, then plummeted by 155.86% to 0.1 in 2022, then tumbled by 140.97% to 0.24 in 2023, then skyrocketed by 108.21% to 0.02 in 2024, then skyrocketed by 3701.35% to 0.76 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.76 in Q4 2025, 0.48 in Q3 2025, and 0.4 in Q2 2025.